First-in-class cancer therapeutic to stimulate natural killer cells

Article Abstract:

The first ever clinical trial of a therapeutic that binds to natural killer (NK) cell receptors is slated to take place before the end of 2006. Its goal is to harness directly the therapeutic potential of NK cells in the treatment of a wide range of immune-related conditions, including cancers, autoimmune disease and infection.

Cell receptors, Immune system

---

Cancer surgery joins the dots

Article Abstract:

The use of quantum dots in performing sentinel lymph node biopsy (SLNB) through optical imaging near-infrared (NIR) fluorescence is presented. It represents not only a pioneering medical application of nanocrystals, but also a step forward in the clinical application of sentinel lymph node biopsy (SLNB) in cancer surgery.

Quantum theory, Quantum mechanics, Lymph node biopsy

---

Erbitux diagnostic latest adjunct to cancer therapy

Article Abstract:

Chimeric antibody Erbitux, which is manufactured by ImClone, has acquired the United States (US) marketing clearance for treating metastatic colorectal cancer. DakoCytomation has received the approval of The US Food and Drug Administration (FDA) for using with Erbitux.

United States, Care and treatment, Colorectal cancer, Drug approval

Similar abstracts:

• Abstracts: An engineered epigenetic transgene switch in mammalian cells. Gas-inducible transgene expression in mammalian cells and mice
• Abstracts: India aims to become the main bioinformatics hub. Off the beaten path. E&Y report backs Asia-Pacific biotech
• Abstracts: Convergence in biomedical technology. Engineering vascularized skeletal muscle tissue. Nanoliter-scale synthesis of arrayed biomaterials and application to human embryonic stem cells
• Abstracts: The return of the biotech scorecard. PEGing biotech growth. How do your stocks really perform?
• Abstracts: The biological magic behind the bullets. Structure-based maximal affinity model predicts small-molecule druggability

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.